Home/Pipeline/Oral RSV Vaccine

Oral RSV Vaccine

Respiratory Syncytial Virus (RSV)

Preclinical/Phase 1Active

Key Facts

Indication

Respiratory Syncytial Virus (RSV)

Phase

Preclinical/Phase 1

Status

Active

Company

Vaxart

About Vaxart

Vaxart's mission is to transform global health by developing oral recombinant pill vaccines that generate mucosal and systemic immunity. The company's core strategy leverages its proprietary delivery platform to create vaccines that are easier to administer, do not require cold-chain logistics, and could potentially reduce transmission of viruses. While still in clinical development, Vaxart aims to address significant unmet needs in infectious diseases with a more accessible and potentially more effective vaccine format.

View full company profile

Therapeutic Areas

Infectious Diseases Gastroenterology

Other Respiratory Syncytial Virus (RSV) Drugs

Drug	Company	Phase	Status
IN-002	Inhalon Biopharma	Pre-IND	Active
BLB201	CyanVac	Phase 1/2	Active